These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 36590956)

  • 1. Regulatory policy and pharmaceutical innovation in the United Kingdom after Brexit: Initial insights.
    Hofer MP; Criscuolo P; Shah N; Ter Wal ALJ; Barlow J
    Front Med (Lausanne); 2022; 9():1011082. PubMed ID: 36590956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. From the European Medicines Agency to Project Orbis: new activities and challenges to facilitate UK oncology drug approval following Brexit.
    Lythgoe MP; Krell J; Bower M; Murphy R; Marriott J; Blagden SP; Aggarwal A; Sullivan R
    Lancet Oncol; 2023 Apr; 24(4):e150-e160. PubMed ID: 36990613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. REACHing for divergence?-UK chemical regulation post-Brexit.
    Jones LB; Burns CJ
    Integr Environ Assess Manag; 2024 Sep; 20(5):1529-1538. PubMed ID: 38712803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. UK medicines regulation: responding to current challenges.
    Richards N; Hudson I
    Br J Clin Pharmacol; 2016 Dec; 82(6):1471-1476. PubMed ID: 27580254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Brexit on UK and EU Drug Regulation and Patient Access.
    Breckenridge A; Feldschreiber P
    Clin Pharmacol Ther; 2019 Apr; 105(4):923-925. PubMed ID: 30346627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulatory Consequences of "Brexit" for the Development of Medicinal Products.
    Jackson EL; Feldschreiber P; Breckenridge A
    Clin Pharmacol Ther; 2017 Aug; 102(2):183-184. PubMed ID: 28555841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Association for Human Pharmacology in the Pharmaceutical Industry London Meeting 2018: Brexit and Other Challenges in Early Phase Drug Development.
    Reijntjes S; Albayaty M; Bush J; Cheriyan J; Cromie A; Koch A; Hammond M; Mair S; Scholes P; Lorch U; Stringer S; Taubel J; Hardman TC
    Front Pharmacol; 2018; 9():1301. PubMed ID: 30510508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Impact of Brexit on the Pharmaceutical Supply Chain of the United Kingdom: Scoping Review Protocol.
    Milne-Ives M; Lam C; van Velthoven M; Meinert E
    JMIR Res Protoc; 2020 Sep; 9(9):e17684. PubMed ID: 32965239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brexit and Animal Welfare Impact Assessment: Analysis of the Threats Brexit Poses to Animal Protection in the UK, EU and Internationally.
    McCulloch SP
    Animals (Basel); 2019 Mar; 9(3):. PubMed ID: 30917541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating the implications of Brexit for research collaboration and policy: a network analysis and simulation study.
    Garas G; Cingolani I; Patel VM; Panzarasa P; Darzi A; Athanasiou T
    BMJ Open; 2019 Sep; 9(9):e025025. PubMed ID: 31506256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EU Clinical Trials Regulation 2014: Fetter or facilitator?
    Cave E
    Med Law Int; 2018 Jun; 18(2-3):179-194. PubMed ID: 30595625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brexit and Animal Welfare Impact Assessment: Analysis of the Opportunities Brexit Presents for Animal Protection in the UK, EU, and Internationally.
    P McCulloch S
    Animals (Basel); 2019 Oct; 9(11):. PubMed ID: 31661920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brexit and Animal Protection: Legal and Political Context and a Framework to Assess Impacts on Animal Welfare.
    McCulloch SP
    Animals (Basel); 2018 Nov; 8(11):. PubMed ID: 30453693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How do we avoid disaster when exiting the European Medicines Agency? Making the most of Brexit in pharmaceutical regulation.
    Hatswell AJ
    Ecancermedicalscience; 2017; 11():ed67. PubMed ID: 28717397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The licensing of medicines in the UK.
    Drug Ther Bull; 2009 Apr; 47(4):45-8. PubMed ID: 19357299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How will Brexit affect health and health services in the UK? Evaluating three possible scenarios.
    Fahy N; Hervey T; Greer S; Jarman H; Stuckler D; Galsworthy M; McKee M
    Lancet; 2017 Nov; 390(10107):2110-2118. PubMed ID: 28965715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EU Health Policy, Coherence, Stakeholder Diversity and Their Impact on the EMA.
    Horgan D; Kent A
    Biomed Hub; 2017; 2(Suppl 1):191-201. PubMed ID: 31988949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 'Bioexit': navigating the policy and regulatory pathways for the biotechnology industry in a post-Brexit landscape.
    Mackey TK; Annaloro J
    Drug Discov Today; 2018 Jul; 23(7):1324-1327. PubMed ID: 29501912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brexit threatens the UK's ability to tackle illicit drugs and organised crime: What needs to happen now?
    Roman-Urrestarazu A; Yang J; Robertson R; McCallum A; Gray C; McKee M; Middleton J
    Health Policy; 2019 Jun; 123(6):521-525. PubMed ID: 31054860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of Brexit on oral health.
    Coughlan J; Shah S
    Br Dent J; 2020 Nov; 229(9):622-626. PubMed ID: 33188346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.